Drug Pricing: Page 3
-
Scott Olson via Getty Images
Medicare reveals results of drug price negotiations
The first round of pricing talks under new powers granted to the U.S. government involved drugs like the blood thinners Eliquis and Xarelto, as well immune medicines like Enbrel and Stelara.
By Ned Pagliarulo • Aug. 15, 2024 -
Getty Images
Cigna CEO promises ‘aggressive’ defense of pharmacy benefit managers
David Cordani’s comments to investors Thursday come as the payer blew past Wall Street’s expectations for the second quarter, helped by significant growth in its health services division — including PBM Express Scripts.
By Rebecca Pifer Parduhn • Aug. 1, 2024 -
Explore the Trendline➔
Elizabeth Regan/BioPharma Dive
TrendlineDrug pricing
President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.
By BioPharma Dive staff -
Getty Images
PBMs battle bipartisan scrutiny as lawmakers eye reforms
Top executives at CVS Caremark, Optum Rx and Express Scripts made a rare congressional appearance to defend their companies’ drug pricing policies.
By Susanna Vogel , Rebecca Pifer Parduhn • July 24, 2024 -
Chris duMond via Getty Images
Where Kamala Harris stands on three key pharma issues
The presumptive Democratic nominee has a history of taking on pharma over drug prices and supporting women’s healthcare access.
By Amy Baxter • July 24, 2024 -
Chip Somodevilla via Getty Images
FTC to sue three largest PBMs over drug price practices: WSJ
Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin, per the report.
By Rebecca Pifer Parduhn • July 10, 2024 -
Getty Images
FTC criticizes PBM power over prescription drug market
On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.
By Rebecca Pifer Parduhn • July 9, 2024 -
Michael M. Santiago via Getty Images
FTC targets ‘junk patents’ on Ozempic, other top drugs
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and COPD.
By Kristin Jensen • May 1, 2024 -
Courtesy of Teva Pharmaceutical
Alvotech deal could heighten biosimilar pressure on Humira
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
By Jonathan Gardner • April 19, 2024 -
Getty Images
Medicare to cover Novo’s obesity drug for some patients
Two weeks after the FDA updated Wegovy’s label, Medicare changed its stance to allow people with a history of heart disease to receive treatment, a shift that could boost access to the fast-selling medicine.
By Ben Fidler • March 22, 2024 -
Getty Images
Orchard sets out to sell world’s priciest gene therapy
Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market.
By Kristin Jensen • March 20, 2024 -
Courtesy of Kroger
Elevance to buy Kroger’s specialty pharmacy
Major pharmacy benefit managers continue to double down on specialty as a reliable source of business amid a growing crop of pharmacy upstarts.
By Rebecca Pifer Parduhn • March 19, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
By Ben Fidler • March 15, 2024 -
Julia Rendleman via Getty Images
Why Cigna is capping cost increases for pricey obesity drugs
The first-of-its-kind move comes as pharmacy benefit managers continue to try to prove their value to clients, and shows how major players are working to meet demand for the fast-selling medicines.
By Rebecca Pifer Parduhn • March 8, 2024 -
Joe Raedle via Getty Images
Biden proposes strengthening Medicare’s drug pricing power
The administration seeks to significantly increase the number of drugs each year that would be subjected to price negotiations under provisions of the Inflation Reduction Act.
By Kristin Jensen • March 7, 2024 -
Getty Images
AstraZeneca’s drug pricing lawsuit dismissed by federal judge
The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.
By Jonathan Gardner • March 4, 2024 -
Kevin Dietsch via Getty Images
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.
By Jonathan Gardner • Feb. 8, 2024 -
Getty Images
New CMS pilot to test payment scheme for pricey sickle cell gene therapies
The agency is planning a pilot program across states to help sickle cell patients access treatments like the newly approved Casgevy and Lyfgenia.
By Ned Pagliarulo • Jan. 31, 2024 -
Getty Images
Sanders threatens to subpoena J&J, Merck CEOs over drug prices
The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.
By Jonathan Gardner • Jan. 19, 2024 -
Getty Images
FDA authorizes Florida to import drugs from Canada
The clearance is a major shift for the agency, which described its decision as a “first step” in allowing Florida to bulk purchase lower-cost Canadian medicines.
By Jonathan Gardner , Ned Pagliarulo • Jan. 5, 2024 -
Anna Moneymaker via Getty Images
Humira leads ICER’s latest list of ‘unsupported’ price hikes
AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.
By Jonathan Gardner • Dec. 11, 2023 -
Getty Images
Pricey new gene therapies for sickle cell pose access test
Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while Bluebird’s competing genetic medicine is priced at $3.1 million.
By Ned Pagliarulo • Dec. 8, 2023 -
Joe Raedle via Getty Images
Biden administration goes after drug patents in bid to lower prices
The White House is supporting a policy that would allow the U.S. government to sidestep patent protections for drugs developed with federal funding and that have prices deemed “extreme, unjustified, and exploitative.”
By Jonathan Gardner • Dec. 7, 2023 -
BIO names longtime Amicus head John Crowley as new CEO
Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.
By Jonathan Gardner • Dec. 5, 2023 -
Courtesy of BioMarin Pharmaceutical
BioMarin secures hemophilia gene therapy coverage in Germany
Drawn-out negotiations led to a lower price than initially expected, but analysts called the agreement a step forward for the biotech company.
By Kristin Jensen • Nov. 29, 2023 -
Getty Images
FTC challenges patents held by nine big drugmakers, citing unfair competition
The agency claims intellectual property for emergency allergy shot EpiPen and asthma medication Advair was “improperly listed” in an FDA database.
By Jonathan Gardner • Nov. 8, 2023
Previous
